Table 1. Clinical characteristics of... | American Society of Hematology

Table 1.

Clinical characteristics of patients who received DLI

Patient no.	Age, y, at BMT/sex	BMT conditioning regimen	Disease status at BMT	GVH disease stage after BMT	BM CD3⁺ cells per kilogram infused	DLI CD4⁺ cells per kilogram infused	Disease status before DLI	Disease status after DLI	Acute GVH disease stage after DLI
1	54/M	CTX/TBI	PR	1	0.30 × 10⁶	3 × 10⁷	PD	CR	2
2	50/M	CTX/TBI	PR	0	0.19 × 10⁶	3 × 10⁷	PR	CR	1
3	46/M	CTX/TBI	PR	1	2.70 × 10⁶	3 × 10⁷	PR	CR	3
4	49/F	CTX/TBI	PR	1	0.30 × 10⁶	3 × 10⁷	SD	PR	0
5	47/F	CTX/TBI	CR	0	0.11 × 10⁶	3 × 10⁷	PD	CR	0
6	42/M	CTX/TBI	CR	0	3.30 × 10⁶	3 × 10⁷	CR	CR	0
7	43/F	CTX/TBI	PR	0	0.20 × 10⁶	3 × 10⁷	SD	PR	3
8	51/M	CTX/TBI	PR	0	0.09 × 10⁶	3 × 10⁷	CR	CR	3
9	46/F	CTX/BUS	PR	0	0.67 × 10⁶	3 × 10⁷	PR	CR	3

Patient no.	Age, y, at BMT/sex	BMT conditioning regimen	Disease status at BMT	GVH disease stage after BMT	BM CD3⁺ cells per kilogram infused	DLI CD4⁺ cells per kilogram infused	Disease status before DLI	Disease status after DLI	Acute GVH disease stage after DLI
1	54/M	CTX/TBI	PR	1	0.30 × 10⁶	3 × 10⁷	PD	CR	2
2	50/M	CTX/TBI	PR	0	0.19 × 10⁶	3 × 10⁷	PR	CR	1
3	46/M	CTX/TBI	PR	1	2.70 × 10⁶	3 × 10⁷	PR	CR	3
4	49/F	CTX/TBI	PR	1	0.30 × 10⁶	3 × 10⁷	SD	PR	0
5	47/F	CTX/TBI	CR	0	0.11 × 10⁶	3 × 10⁷	PD	CR	0
6	42/M	CTX/TBI	CR	0	3.30 × 10⁶	3 × 10⁷	CR	CR	0
7	43/F	CTX/TBI	PR	0	0.20 × 10⁶	3 × 10⁷	SD	PR	3
8	51/M	CTX/TBI	PR	0	0.09 × 10⁶	3 × 10⁷	CR	CR	3
9	46/F	CTX/BUS	PR	0	0.67 × 10⁶	3 × 10⁷	PR	CR	3

CTX indicates cyclophosphamide; BUS, busulfan; TBI, total body irradiation; SD, stable disease; PD, progressive disease; PR, partial response; and CR, complete response.